Skip to main content

Practice

JAK Inhibitor Misses Endpoint in Safety Study. Now What?

MedPage Today
Jan 27, 2021

Pfizer announced results Wednesday from its FDA-mandated postmarketing safety study of tofacitinib (Xeljanz), and they don't bode well for the drug and possibly others in its class.



Compared with patients taking tumor necrosis factor (TNF) inhibitors, those assigned to tofacitinib (5

Read Article

Urate Lowering Therapy During Acute Gout

Jan 26, 2021

Acute gout has its well defined protocols, and most state that urate lowering therapy (ULT) should be continued; but does ULT affect outcomes in an acute gout attack?

Read Article

Rheumatologists Rank 2nd in Physician Burnout

Jan 26, 2021

The 2021 Medscape Survey on Physician burnout ranks rheumatology second, just behind Critical Care medicine.

The survey included over 12,000 physcians from 20 specialties. While 42% of MDs claimed to be burnt-out, Rheumatologists claimed this 50% of the time. The top 3 this year were Critical

Read Article

Protective Effects of Colchicine in Non-Hospitalized COVID-19

Jan 25, 2021

A press release from Montreal Heart Institute announced that the COLCORONA clinical trial provided evidence of the protective effect of colchicine; demonstrating a 21% reduced risk of death or hospitalizations in patients with COVID-19 compared to placebo. COLCORONA trial was a contact-less,

Read Article

Voclosporin FDA Approved for Lupus Nephritis

Jan 24, 2021

On January 22nd, the FDA approved voclosporin (Lupkynis) for use in adults with active lupus nephritis; voclosporin is a calcineurin-inhibitor immunosuppressant indicated for use in combination with a background immunosuppressive therapy. FDA approval was based on data from the pivotal AURORA

Read Article

RheumNow Podcast – Don’t Hold the Benlysta, Take the Vaccine (1.22.2021)

Jan 22, 2021

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com, with more than a dozen items to discuss on this week's podcast.

Read Article

NEJM: Early Combo Monoclonal Antibody Therapy in COVID-19

Jan 21, 2021

NEJM has published the interim analysis of the REGN-COV2 trial, wherein an antibody cocktail reduced viral loads with less clinical consequences. 



Recent data suggest that high viral loads are associated with greater risk for COVID-19 complications and death. A combination of two

Read Article

Combo Anti-Spike Protein Antibody for Mild to Moderate COVID-19

Jan 21, 2021

JAMA has published the BLAZE-1 study, showing significant SARS-CoV-2 viral load reduction at day 11 and less COVID-19 progression when combination anti-spike monoclonal antibody therapy (bamlanivimab and etesevimab) was given to mild to moderate, non-hospitalized COVID-19 patients.

Read Article
Though provoking piece by Dr. Len Calabrese in Healio,He references Drs. Schett and Scher writing in Nature Reviews Rheumatology on KOLs. Both articles are about reflection on what we do, how we do it, what motivates us. Good Reads https://t.co/HDlFRVJq1a https://t.co/CtqqiZuxwo

Dr. John Cush RheumNow ( View Tweet)

Jan 21, 2021
Inequities in Telemedicine During COVID-19 Health equity in the telehealth age has assumed added importance since the COVID-19 pandemic began but what if you don't have access to reliable technology? The problem spreads beyond that though. https://t.co/L8nvUbOqHA https://t.co/SZSmerQGEY
Dr. John Cush RheumNow ( View Tweet)
Jan 21, 2021

Low Risk of TB with Secukinumab

Jan 20, 2021

JAMA Dermatology has reported on a longitudinal cohort study of 12,319 secukinumab (SEC) treated patients (psoriasis, psoriatic arthritis, or ankylosing spondylitis); no new cases of active tuberculosis (TB) and very few cases of latent tuberculosis infection (LTBI) were found. 

Read Article

Mortality Risk in Rheumatoid Lung Patients

Jan 20, 2021

A Medicare claims analysis of rheumatoid arthritis (RA) patients showed that RA-associated interstitial lung disease (RA-ILD) was seen in nearly 5% of patients and was found to increase mortality risks, including respiratory and cancer mortality not explained by other factors.



Sparks

Read Article

Factors Predictive of SLE Flare After HCQ Taper/Discontinuation

MedPage Today
Jan 19, 2021

The benefits of hydroxychloroquine in lupus are many, but if you were to withdraw HCQ? A recent study of five Canadian cohorts, suggests that certain baseline variables, including age, race, and steroid use,  were predictive of flare in patients with SLE who tapered or discontinued treatment

Read Article

Inequities in Telemedicine During COVID-19

MedPage Today
Jan 19, 2021

Health equity in the telehealth age has assumed added importance since the COVID-19 pandemic began. The Federal Communications Commission estimates that about 21 million Americans don't have access to the Internet in their homes. Other sources estimate it is closer to 162 million. However,

Read Article

Travel During COVID-19 Pandemic

Jan 18, 2021

The CDC has addressed the effects and the issues of domestic and international travel on its website.  Below is a sampling of key advice.

Read Article

Copay Assistance Programs Help Patients but Confuse Them Too

MedPage Today
Jan 15, 2021

"If you're having trouble paying for your medications, Drug Company X may be able to help."



You may have heard sentences like this at the end of pharmaceutical ads on television, and some clinicians may wonder what exactly the companies do to help their patients. The help usually

Read Article

2020 Rheumatology Year in Review

Jan 14, 2021

2020 was historic, memorable and game-changing. Under the cloud of COVID-19, there were many significant and memorable advances and setbacks for the rheumatology world. In our accounting of most read articles for 2020, (not surprisingly) 17/20 were COVID-related. Below, are our top news items

Read Article

ProDERM Study: IVIG in Dermatomyositis

Jan 13, 2021

The ProDERM study design and outcomes are previewed in Medicine; and as promised the results were revealed at ACR Convergence in November 2020 showing that IVIg is safe, effective and superior to placebo i(PBO) in patients with dermatomyositis (DM).

Read Article

Long Term Safety and Efficacy of Tacrolimus in Lupus Nephritis

Jan 13, 2021

Takeuchi et al has published their large experience with long-term tacrolimus use in lupus nephritis patients showing its real-world safety and efficacy.



This oopen-label, observational, cohort study from 275 sites in Japan, included 1355 systemic lupus erythematosus (SLE) patients

Read Article
Telemedicine study on accuracy of Pt reported swelling predicting inflamm arthritis. 1637 pts w/ 13 wks of Sxs. 76% pts reported swelling, but only found by 41% of Rheums. Pt reporting sensitivity was was 87%, but specificity only 31%; PPV=46%, NPV=77% https://t.co/oV3p06BHRj

Dr. John Cush RheumNow ( View Tweet)

Jan 13, 2021

Delays in Diagnosis of Axial Spondyloarthritis

Jan 12, 2021

The diagnosis of axial spondyloarthritis (and anklylosing spondylitis) (axSpA) is often delayed and usually not diagnosed by rheumatologists; a recent metanalysis shows that longer delays were attributable to lower education levels, younger age at onset and absence of extra-articular

Read Article

Hydroxychloroquine Shortage During COVID-19

Jan 12, 2021

According to a recent report in Annals of Rheumatic Disease, public enthusiasm for hydroxychloroquine (HCQ) created significant access issues for rheumatic patients in the early phases of the COVID-19 pandemic.



Despite public, political and quasi research evidence supporting

Read Article

Adipose Transplants as a New Regulator of Osteoarthritis

Jan 11, 2021

A novel report from PNAS suggests that in osteoarthritis (OA), the damage is not entirely from body weight and mechanics, instead it may be from adipose tissue itself.

Read Article

Corticosteroid Use Hikes CV Risks in Rheumatic Patients

Jan 11, 2021

UK Clinical Practice Research Datalink population study shows that patients with immune-mediated inflammatory diseases, such as RA, PMR, GCA and IBD, have an augmented risk of CV outcomes with glucocorticoid use; even lower doses had a near doubling of their underlying CVD risk.

Read Article

Medicare's 'Most Favored Nation' Drug-Pricing Rule in Limbo

MedPage Today
Jan 08, 2021

The fate of the Trump administration's "most favored nation" (MFN) rule for bringing down prescription drug prices remains uncertain as President-elect Joe Biden prepares to assume office later this month.

Read Article
×